^
    3ms
    BGB-3245-AU-001: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors (clinicaltrials.gov)
    P1, N=109, Terminated, MapKure, LLC | Active, not recruiting --> Terminated; The study was terminated by the sponsor for reasons unrelated to safety.
    Trial termination • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion
    |
    brimarefenib (BGB-3245)
    8ms
    BGB-3245-EGFR-001: A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers (clinicaltrials.gov)
    P1, N=13, Terminated, MapKure, LLC | N=64 --> 13 | Trial completion date: May 2027 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: May 2027 --> Mar 2025; Funding terminated due to business reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Vectibix (panitumumab) • brimarefenib (BGB-3245)
    10ms
    Mirdametinib + BGB-3245 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=23, Terminated, SpringWorks Therapeutics, Inc. | Trial completion date: Jun 2027 --> Jan 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2025; Lack of tolerability of Brimarafenib when given in combination of Mirdametinib
    Trial completion date • Trial termination • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • BRAF fusion
    |
    Gomekli (mirdametinib) • brimarefenib (BGB-3245)
    10ms
    BGB-3245-AU-001: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, MapKure, LLC | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion
    |
    brimarefenib (BGB-3245)
    1year
    Mirdametinib + BGB-3245 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=23, Active, not recruiting, SpringWorks Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=136 --> 23
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • BRAF fusion
    |
    Gomekli (mirdametinib) • brimarefenib (BGB-3245)
    1year
    BGB-3245-AU-001: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors (clinicaltrials.gov)
    P1, N=114, Recruiting, MapKure, LLC | Trial primary completion date: Aug 2024 --> Jun 2025
    Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion
    |
    brimarefenib (BGB-3245)
    over1year
    A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers (clinicaltrials.gov)
    P1, N=64, Recruiting, MapKure, LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Vectibix (panitumumab) • brimarefenib (BGB-3245)
    almost2years
    A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers (clinicaltrials.gov)
    P1, N=64, Not yet recruiting, MapKure, LLC
    New P1 trial • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Vectibix (panitumumab) • brimarefenib (BGB-3245)
    almost2years
    BGB-3245-AU-001: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors (clinicaltrials.gov)
    P1, N=114, Recruiting, MapKure, LLC | Phase classification: P1a/1b --> P1
    Phase classification
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion
    |
    brimarefenib (BGB-3245)
    over2years
    BGB-3245-AU-001: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors (clinicaltrials.gov)
    P1a/1b, N=114, Recruiting, MapKure, LLC | Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: May 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion
    |
    brimarefenib (BGB-3245)
    over2years
    BGB-3245-AU-001: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors (clinicaltrials.gov)
    P1a/1b, N=114, Recruiting, MapKure, LLC | N=168 --> 114
    Enrollment change • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion
    |
    brimarefenib (BGB-3245)
    almost3years
    Mirdametinib + BGB-3245 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=136, Recruiting, SpringWorks Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • BRAF fusion
    |
    Gomekli (mirdametinib) • brimarefenib (BGB-3245)